Dr. Shirit Einav publishes review of repurposed drugs for COVID
Posted on August 12th, 2020
SPARK Scholar Shirit Einav, a virologist focusing on host-targeted drugs as broad antivirals, and Stanford researcher Sirle Saul published a review in ACS Infectious Diseases looking at old drugs for a new virus: can repurposed approaches combat COVID-19?
The review summarizes the major repurposed approaches that have been proposed or are already being studied in clinical trials for COVID-19. These include drugs to reduce SARS-CoV-2 replication by targeting either viral enzymatic functions or cellular factors required for the viral life cycle, or drugs that modulate the host immune response to SARS-CoV-2 infection, which could enhance viral clearance or prevent excessive inflammation and tissue injury. The authors also discuss ongoing challenges associated with the off-label use of existing drugs in the context of the COVID-19 outbreak.
Permalink: https://sparkmed.stanford.edu/dr-shirit-einav-publishes-review-of-repurposed-drugs-for-covid/